Galapagos wins 2012 European Mediscience Awards

Mechelen, Belgium and London, UK; 22 June 2012 – Galapagos NV (Euronext: GLPG) announced today that it won the European Mediscience Awards for Transaction of the year and Chief Executive of the year at last night’s ceremony in London.  The Transaction of the year award recognizes the global collaboration with Abbott for selective JAK1 inhibitor GLPG0634.  The Chief Executive of the year award recognizes the leadership and other qualities demonstrated by Onno van de Stolpe.

“We are pleased to have won two European Mediscience awards, which also acknowledge the efforts of the entire Galapagos team,” said Dr Raj Parekh, Chairman of the Board of Directors of Galapagos.  “Galapagos is executing its strategy to become a European leader in biotech, and these awards recognize the progress Galapagos is making toward achieving that ambition.”

About the European Mediscience Awards
The European Mediscience Awards have been held since 2002 and celebrate the best in the quoted life science, healthcare and biotech industries.  The event has grown to be the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe, attracting over 500 attendees.  More info at:

About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action.  The Company is progressing GLPG0634, as well as one of the largest pipelines in biotech, with four programs in development and over 30 discovery programs.  The Galapagos Group has about 800 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium.  More info at:


Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028

Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240

This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.